Ken Griffin Rocket Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.6 - $25.88 $47,520 - $69,876	2,700 Added 13.3%	23,000 $424,000
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $557,820 - $721,440	-27,000 Reduced 57.08%	20,300 $437,000
Q1 2024 May 15, 2024	BUY	$26.16 - $30.74 $468,264 - $550,246	17,900 Added 60.88%	47,300 $1.27 Million
Q4 2023 Feb 14, 2024	SELL	$16.78 - $31.94 $1.02 Million - $1.94 Million	-60,700 Reduced 67.37%	29,400 $881,000
Q3 2023 Nov 14, 2023	BUY	$15.07 - $24.05 $984,071 - $1.57 Million	65,300 Added 263.31%	90,100 $1.85 Million
Q2 2023 Aug 14, 2023	BUY	$16.59 - $23.6 $155,946 - $221,840	9,400 Added 61.04%	24,800 $492,000
Q1 2023 May 15, 2023	SELL	$15.79 - $22.6 $224,218 - $320,920	-14,200 Reduced 47.97%	15,400 $263,000
Q4 2022 Feb 14, 2023	SELL	$15.5 - $22.76 $418,500 - $614,520	-27,000 Reduced 47.7%	29,600 $579,000
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $467,585 - $695,898	37,800 Added 201.06%	56,600 $903,000

209

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.